NEJM AI to Educate Clinicians about Artificial Intelligence Applications in Medicine

NEJM Group, publisher of the New England Journal of Medicine, today announced the launch of its newest title, NEJM AI, a peer-reviewed, monthly journal dedicated to the latest research and application of artificial intelligence (AI) and machine learning in medicine. In addition to original research articles, the journal publishes reviews, policy perspectives and educational material for clinicians, scientists, health care leaders, policy makers, regulators, and executives with pharmaceutical, device-manufacturing and technology companies. Benchmark data sets and protocols are a unique feature of the journal and are freely available to practitioners to help with testing and advancing medical AI knowledge.

"What many people don’t know is that AI is already being used in medicine," said Eric Rubin, M.D., Ph.D., editor-in-chief of the New England Journal of Medicine and NEJM Group publications. "Our newest peer-reviewed journal, NEJM AI, will cover this rapidly changing field to deliver trusted, high-quality evidence and educational material to clinicians with the aim of improving health care for patients worldwide."

In the past decade, the Food and Drug Administration has approved AI-powered devices capable of reading medical imaging and assisting clinicians in making diagnoses. While many of these devices and programs meet regulatory standards, the medical community has been slow to see the potential of AI medical applications or adopt them. NEJM AI aims to be an essential resource for medical professionals who want an in-depth understanding of how breakthrough clinical applications in AI/ML will be evaluated to inform clinical practice.

"We're at a pivotal time in medicine with a new participant in medical decision making," said NEJM AI editor-in-chief, Isaac (Zak) Kohane, M.D., Ph.D. "AI is not a fad. It will revolutionize the way medicine is practiced and change the doctor-patient relationship. NEJM AI will apply the same rigorous standards as our flagship journal to determine which AI tools are ready for use in medical settings." Additional insights from Dr. Kohane and the editors are provided in these editorials by Kohane and Koller.

According to Statista, the market for AI in healthcare in 2021 was $11 billion (USD) worldwide, with that number expected to reach $188 billion by 2030. "With such growth, it's important that AI tools meet the same bar for medical evidence that is expected from other clinical interventions," said Charlotte Haug, M.D., Ph.D., Executive Editor of NEJM AI. "Our editorial team of clinical and biomedical informatics experts seeks to publish the most important trials designed to test an AI tool against an established standard, meeting high safety standards."

Community members are encouraged to listen to NEJM AI Grand Rounds, a podcast hosted by deputy editors Arjun (Raj) Manrai, Ph.D. and Andrew Beam, Ph.D., featuring informal conversations with experts exploring issues at the intersection of artificial intelligence, machine learning, and medicine. The journal also hosts virtual events to open dialogue around the value, ethics, and quality of medical AI.

NEJM AI will provide a range of perspectives on the critical ethical and legal challenges and risks around the development and deployment of AI in a clinical setting. Stimulating conversations among clinicians who use medical AI, developers of the technology, and patients who benefit from these applications is the mission of NEJM AI. Researchers are invited to submit their manuscripts for consideration or email This email address is being protected from spambots. You need JavaScript enabled to view it. with questions for the editors. Those with an interest in keeping abreast of this rapidly changing field may sign up for the newsletter or subscribe to NEJM AI.

About NEJM Group

NEJM Group creates high-quality medical resources for research, learning, practice and professional development designed to meet the demand for essential medical knowledge among academic researchers and teachers, physicians, clinicians, executives and others in medicine and health care. NEJM Group products include the New England Journal of Medicine, NEJM Evidence, NEJM AI, NEJM Catalyst, NEJM Journal Watch, NEJM Knowledge+, NEJM Healer, NEJM Resident 360, NEJM Yi Xue Qian Yan and NEJM Career Center. NEJM Group is a division of the Massachusetts Medical Society. For more information visit www.nejmgroup.org.

About NEJM AI

NEJM AI is an interdisciplinary journal that bridges fast-moving developments in AI, informatics, and technology in medicine with the application of these advancements to clinical practice. NEJM AI covers the application of AI methodologies and data science to biomedical informatics, connected health, telemedicine, medical images and imaging, personalized medicine, policy and regulation, and the ethical and medicolegal implications of AI. Visit https://ai.nejm.org for more details.

Most Popular Now

Mobile App Tracking Blood Pressure Helps…

The AHOMKA platform, an innovative mobile app for patient-to-provider communication that developed through a collaboration between the School of Engineering and leading medical institutions in Ghana, has yielded positive results...

Accelerating NHS Digital Maturity: Paper…

Digitised clinical noting at South Tees Hospitals NHS Foundation Trust is creating efficiencies for busy doctors and nurses. The trust’s CCIO Dr Andrew Adair, deputy CCIO Dr John Greenaway, and...

Customized Smartphone App Shows Promise …

A growing body of research indicates that older adults in assisted living facilities can delay or even prevent cognitive decline through interventions that combine multiple activities, such as improving diet...

AI Tool Helps Predict Who will Benefit f…

A study led by UCLA investigators shows that artificial intelligence (AI) could play a key role in improving treatment outcomes for men with prostate cancer by helping physicians determine who...

New Study Shows Promise for Gamified mHe…

A new study published in Multiple Sclerosis and Related Disorders highlights the potential of More Stamina, a gamified mobile health (mHealth) app designed to help people with Multiple Sclerosis (MS)...

AI in Healthcare: How do We Get from Hyp…

The Highland Marketing advisory board met to consider the government's enthusiasm for AI. To date, healthcare has mostly experimented with decision support tools, and their impact on the NHS and...

Research Shows AI Technology Improves Pa…

Existing research indicates that the accuracy of a Parkinson's disease diagnosis hovers between 55% and 78% in the first five years of assessment. That's partly because Parkinson's sibling movement disorders...

New AI Tool Accelerates Disease Treatmen…

University of Virginia School of Medicine scientists have created a computational tool to accelerate the development of new disease treatments. The tool goes beyond current artificial intelligence (AI) approaches by...

DMEA sparks: The Future of Digital Healt…

8 - 10 April 2025, Berlin, Germany. Digitalization is considered one of the key strategies for addressing the shortage of skilled workers - but the digital health sector also needs qualified...

First Therapy Chatbot Trial Shows AI can…

Dartmouth researchers conducted the first clinical trial of a therapy chatbot powered by generative AI and found that the software resulted in significant improvements in participants' symptoms, according to results...

Who's to Blame When AI Makes a Medi…

Assistive artificial intelligence technologies hold significant promise for transforming health care by aiding physicians in diagnosing, managing, and treating patients. However, the current trend of assistive AI implementation could actually...

DeepSeek: The "Watson" to Doct…

DeepSeek is an artificial intelligence (AI) platform built on deep learning and natural language processing (NLP) technologies. Its core products include the DeepSeek-R1 and DeepSeek-V3 models. Leveraging an efficient Mixture...